KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Non Operating Income (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Non Operating Income for 13 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 82.8% year-over-year to $11.1 million, compared with a TTM value of $11.6 million through Dec 2025, up 249.05%, and an annual FY2025 reading of $11.6 million, up 249.05% over the prior year.
  • Non Operating Income was $11.1 million for Q4 2025 at Travere Therapeutics, up from $47000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $11.4 million in Q3 2022 and bottomed at -$17.2 million in Q4 2021.
  • Average Non Operating Income over 5 years is $458800.0, with a median of $379000.0 recorded in 2024.
  • Peak annual rise in Non Operating Income hit 405.08% in 2021, while the deepest fall reached 3060.53% in 2021.
  • Year by year, Non Operating Income stood at -$17.2 million in 2021, then surged by 105.06% to $872000.0 in 2022, then soared by 57.57% to $1.4 million in 2023, then skyrocketed by 340.61% to $6.1 million in 2024, then skyrocketed by 82.8% to $11.1 million in 2025.
  • Business Quant data shows Non Operating Income for TVTX at $11.1 million in Q4 2025, $47000.0 in Q3 2025, and -$85000.0 in Q2 2025.